BRCA1 and hypoparathyroidism-retardation-dysmorphism syndrome: Based on the high dependency of BRCA1/2‐mutated tumors on PARP proteins, PARPi have demonstrated significant clinical efficacy in treating HRD tumors, effectively overcoming chemoresistance and significantly prolonging patient survival [68].